A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.

PHASE2CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

July 3, 2014

Primary Completion Date

September 20, 2015

Study Completion Date

December 22, 2015

Conditions
Neutropenia
Interventions
BIOLOGICAL

F-627

F-627 at doses of 10 mg/dose or 20 mg/dose, s.c. on Day 3 of each cycle for up to 4 cycles.

BIOLOGICAL

Filgrastim

Filgrastim at dose of 5 mcg/kg/day for up to 2 weeks, s.c. start from Day 3 of each cycle for up to 4 cycles.

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
collaborator

Fudan University

OTHER

collaborator

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

OTHER

collaborator

Nanfang Hospital, Southern Medical University

OTHER

collaborator

The Affiliated Hospital of Qingdao University

OTHER

collaborator

Tongji Hospital

OTHER

collaborator

The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China

OTHER

collaborator

RenJi Hospital

OTHER

collaborator

Zhejiang Cancer Hospital

OTHER

collaborator

Yunnan Cancer Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Jiangsu Provincial People's Hospital

OTHER

collaborator

Huaxi Hospital

OTHER

lead

EVIVE Biotechnology

INDUSTRY